Gynecological Endocrinology: From Physiological Mechanisms to Clinical Practice

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: 29 August 2025 | Viewed by 1432

Special Issue Editor


E-Mail
Guest Editor
Department of Endocrinology, Medical University of Sofia, Sofia, Bulgaria
Interests: reproductive endocrinology; metabolic syndrome; rare endocrine diseases

Special Issue Information

Dear Colleagues,

Gonadal endocrine diseases in women encompass a broad spectrum of common and rare conditions associated with ovarian dysfunction, sex hormonal disbalance, and infertility. Polycystic ovarian syndrome (PCOS) affects many young women, and its clinical manifestations not only include different signs of hyperandrogenism and menstrual disturbances but also an increased risk of metabolic complications. Even though congenital adrenal hyperplasia and androgen-producing tumors are rarely found, they should be considered in the differential diagnosis of hyperandrogenic PCOS. Despite apparent clinical symptoms, the genetic basis and epigenetic modifications leading to PCOS are far from clear. Further studies are therefore needed to enlighten the etiology and pathophysiology of this heterogeneous condition—particularly, those leading to new therapeutic opportunities for patients.

Beyond hyperandrogenic states, ovarian dysfunction might also result from disturbances in the hypothalamic–pituitary axis caused by a variety of factors. Continuous stress, eating disorders, as well as intensive physical activity might suppress the hypothalamic neurons regulating the pituitary, thus leading to hypothalamic amenorrhea. On the other hand, rare genetic mutations might cause an isolated hypogonadotropic hypogonadism in some female patients, which can be easily overlooked, especially in women undergoing long-term hormonal treatment. 

Premature ovarian failure (POF) can not only be a devastating diagnosis for women with infertility but it could also have profound adverse effects on cardiovascular and bone health. Therefore, more effort should be invested into the development of new diagnostic tools for the early evaluation of ovarian follicular reserve and appropriate treatment.

Accordingly, this Special Issue focuses on the pathophysiology, clinical characteristics, biomarkers, and possible treatment of different ovarian disorders associated with endocrine disturbances. The topic includes (but is not limited to) PCOS, hypothalamic amenorrhea, congenital adrenal hyperplasia, hypogonadotropic hypogonadism, and premature ovarian insufficiency (POI). Extending knowledge in gynecological endocrinology is essential for improving women’s health; therefore, every valuable paper on the topic is welcomed.

Dr. Ralitsa Robeva
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PCOS
  • hypothalamic amenorrhea
  • congenital adrenal hyperplasia
  • hypogonadotropic hypogonadism
  • premature ovarian insufficiency (POI)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1209 KiB  
Article
Central Serous Chorioretinopathy in Endometriosis Treatment with Progestogen: A Metabolic Understanding
by Francesco Chiara, Sarah Allegra, Maura Caudana, Jacopo Mula, Davide Turco, Simona Liuzzi, Maria Paola Puccinelli, Giulio Mengozzi and Silvia De Francia
Life 2025, 15(2), 144; https://doi.org/10.3390/life15020144 - 22 Jan 2025
Viewed by 915
Abstract
Endometriosis afflicts 10% of women in their reproductive years and nearly half of women with infertility, and its etiology is not yet clear. Pharmacological therapy is generally based on progestins like progestogen. This drug binds to progesterone receptors with many known side effects. [...] Read more.
Endometriosis afflicts 10% of women in their reproductive years and nearly half of women with infertility, and its etiology is not yet clear. Pharmacological therapy is generally based on progestins like progestogen. This drug binds to progesterone receptors with many known side effects. Here, we describe the case of a 33-year-old woman surgically treated for endometriosis who continued with drug therapy based on estradiol valerate and dienogest. Approximately 21 months after treatment, she reported ocular symptoms with vision alteration, diplopia, and metamorphopsia related to central serous chorioretinopathy (CSC). After the discontinuation of combined progestin-based treatment, the CSC fully subsided. Semeiological, clinical, and laboratory approaches were adopted, and urinary steroids were measured. A slight increase in prolactinemia in the absence of macro-prolactinemia was reported. The steroidal profile appeared without abnormalities, although a slight alteration of estrogen balance was noted. Considering the pharmacodynamics of dienogest versus selective progesterone receptor modulators, it can be assumed that patients’ clinical events are related to specific site response to steroids that bind the progesterone receptor. Dienogest may have induced the CSC as a not yet characterized side effect of the drug. Undoubtedly, further specific studies are needed concerning the metabolic and pharmacodynamic aspects that cannot be exhaustively covered here. Full article
Show Figures

Figure 1

Back to TopTop